Section of Urology, University of Chicago Medical Center, Chicago, IL, USA.
Urology. 2011 Nov;78(5):977-84. doi: 10.1016/j.urology.2011.04.073. Epub 2011 Sep 3.
Although open radical cystectomy (ORC) remains the gold-standard management of muscle-invasive bladder cancer, the number of centers performing robotic-assisted radical cystectomy (RARC) has recently increased, prompting greater oncological outcome concerns. Although limited in patient number and follow-up, short-term RARC data from centers of excellence appear to show the approach to be safe and effective, with improved perioperative and functional outcomes, while maintaining comparable oncologic efficiency. Nevertheless, despite the surge of centers adopting RARC, the long-term effectiveness of minimally-invasive techniques has yet to be proven. This review of published RARC series affirms the need for prospective, long-term, controlled studies to adequately evaluate the role of robotics in bladder cancer surgery.
虽然开放性根治性膀胱切除术(ORC)仍然是肌层浸润性膀胱癌的金标准治疗方法,但最近施行机器人辅助根治性膀胱切除术(RARC)的中心数量有所增加,这引发了人们对肿瘤学结果的更多关注。尽管卓越中心的短期 RARC 数据在患者数量和随访方面受到限制,但这些数据似乎表明该方法是安全有效的,具有改善的围手术期和功能结果,同时保持相当的肿瘤学效率。然而,尽管越来越多的中心采用 RARC,但微创技术的长期效果仍有待证明。对已发表的 RARC 系列的回顾证实,需要进行前瞻性、长期、对照研究,以充分评估机器人技术在膀胱癌手术中的作用。